Evidence map›Paper›PMID 30755367›Full record

ArticleVaccine2019

Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014-2015 Ebola outbreak in Sierra Leone.

Mohamed F Jalloh, Mohammad B Jalloh, Alison Albert, Brent Wolff, Amy Callis, Aparna Ramakrishnan, Emily Cramer, Paul Sengeh, Samuel Abu Pratt, Lansana Conteh and 5 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Mohamed F JallohU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. Electronic address: yum8@cdc.gov.
Mohammad B JallohFOCUS 1000, Freetown, Sierra Leone.
Alison AlbertU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Brent WolffU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Amy CallisU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Aparna RamakrishnanU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Emily CramerU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Paul SengehFOCUS 1000, Freetown, Sierra Leone.
Samuel Abu PrattFOCUS 1000, Freetown, Sierra Leone.
Lansana ContehMinistry of Health and Sanitation, Freetown, Sierra Leone.
Rana HajjehU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Rebecca BunnellU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
John T ReddU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Anna Mia EkströmDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; Department of Infectious diseases, Karolinska University Hospital, Sweden.
Helena NordenstedtDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Centers for Disease Control and Prevention · USKarolinska Institutet · SEKarolinska University Hospital · SEMinistry of Health and Sanitation · SL

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

introductionExperimental Ebola vaccines were introduced during the 2014-2015 Ebola outbreak in West Africa. Planning for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) was underway in late 2014. We examined hypothetical acceptability and perceptions of experimental Ebola vaccines among health care workers (HCWs), frontline workers, and the general public to guide ethical communication of risks and benefits of any experimental Ebola vaccine.

methodsBetween December 2014 and January 2015, we conducted in-depth interviews with public health leaders (N = 31), focus groups with HCWs and frontline workers (N = 20), and focus groups with members of the general public (N = 15) in Western Area Urban, Western Area Rural, Port Loko, Bombali, and Tonkolili districts. Themes were identified using qualitative content analysis.

resultsAcross all participant groups, not knowing the immediate and long-term effects of an experimental Ebola vaccine was the most serious concern. Some respondents feared that experimental vaccines may cause Ebola, lead to death, or result in other adverse events. Among HCWs, not knowing the level of protection provided by experimental Ebola vaccines was another concern. HCWs and frontline workers were motivated to help find a vaccine for Ebola to help end the outbreak. General public participants cited positive experiences with routine childhood immunization in Sierra Leone. DISCUSSION: Our formative assessment prior to STRIVE's implementation in Sierra Leone helped identify concerns, motivations, and information gaps among potential participants of an experimental Ebola vaccine trial, at the time when an unprecedented outbreak was occurring in the country. The findings from this assessment were incorporated early in the process to guide ethical communication of risks and benefits when discussing informed consent for possible participation in the vaccine trial that was launched later in 2015.

Indexed as

AdultDisease OutbreaksEbola VaccinesFemaleFocus GroupsHealth PersonnelHemorrhagic Fever, EbolaHumansInterviews as TopicMalePatient Acceptance of Health CareSierra LeoneYoung AdultEbola VaccinesAcceptabilityAttitudesEbola vaccinePerceptionsSierra Leone

Identifiers

PMID30755367
PMCPMC7393388
OpenAlexW2911884272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.